Phase II study of sunitinib as second-line treatment for advanced gastric cancer

by Bang, Yung-Jue, Kang, Yoon-Koo, Kang, Won K., Boku, Narikazu, Chung, Hyun C., Chen, Jen-Shi, Doi, Toshihiko, Sun, Yan, Shen, Lin, Qin, Shukui, Ng, Wai-Tong, Tursi, Jennifer M., Lechuga, Maria J., Lu, Dongrui Ray, Ruiz-Garcia, Ana, Sobrero, Alberto
Published 2021

Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10

by Wainberg, Zev A., Fuchs, Charles S., Tabernero, Josep, Shitara, Kohei, Muro, Kei, Van Cutsem, Eric, Bang, Yung-Jue, Chung, Hyun Cheol, Yamaguchi, Kensei, Varga, Eniko, Chen, Jen-Shi, Hochhauser, Daniel, Thuss-Patience, Peter, Al-Batran, Salah-Eddin, Garrido, Marcelo, Kher, Uma, Shih, Chie-Schin, Shah, Sukrut, Bhagia, Pooja, Chao, Joseph
Published 2022

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.

by Raymond, Eric, Dahan, Laetitia, Raoul, Jean-Luc, Bang, Yung-Jue, Borbath, Ivan, Lombard-Bohas, Catherine, Valle, Juan, Metrakos, Peter, Smith, Denis, Vinik, Aaron, Chen, Jen-Shi, Hoersch, Dieter, Hammel, Pascal, Wiedenmann, Bertram, Van Cutsem, Eric, Patyna, Shem, Lu, Dongrui Ray, Blanckmeister, Carolyn, Chao, Richard, Ruszniewski, Philippe
Published 2021

A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

by Chen, Jen-Shi, Chao, Yee, Bang, Yung-Jue, Roca, Enrique, Chung, Hyun C., Palazzo, Felipe, Kim, Yeul H., Myrand, Scott P., Mullaney, Brian P., Shen, Li J., Linn, Carlos
Published 2021

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study

by Bang, Yung-Jue, Li, Chung-Pin, Lee, Kyung-Hun, Chiu, Chang-Fang, Park, Joon Oh, Shan, Yan-Shen, Kim, Jun Suk, Chen, Jen-Shi, Shim, Hyun-Jeong, Rau, Kun-Ming, Choi, Hye Jin, Oh, Do-Youn, Belanger, Bruce, Chen, Li-Tzong
Published 2021

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

by Noh, Sung Hoon, Park, Sook Ryun, Yang, Han-Kwang, Chung, Hyun Cheol, Chung, Ik-Joo, Kim, Sang-Woon, Kim, Hyung-Ho, Choi, Jin-Hyuk, Kim, Hoon-Kyo, Yu, Wansik, Lee, Jong Inn, Shin, Dong Bok, Ji, Jiafu, Chen, Jen-Shi, Lim, Yunni, Ha, Stella, Bang, Yung-Jue, the CLASSIC trial investigators
Published 2021